Helping people in need !!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This should keep you busy until ATHX announces GOOD NEWS ..GOOD LUCK LONGS
Put in the year that you finished secondary school ... ENJOY
Then press “Hit Me.”
Then click on the plus sign in a picture.
http://thenostalgiamachine.com/
https://www.reddit.com/r/ATHX/comments/q80ze7/confidence_backed_by_research_and_results/?%24deep_link=true&correlation_id=c6864168-8fdc-45ab-9e3b-302ea48c0251&post_fullname=t3_q80ze7&post_index=1&ref=email_digest&ref_campaign=email_digest&ref_source=email&utm_content=post_title&%243p=e_as&_branch_match_id=829669447967134701
Price target is going A LOT higher SOONER than LATER .... GOOD LUCK LONGS
https://www.investorsobserver.com/news/stock-update/do-analysts-agree-wednesday-on-athersys-inc-athx-stocks-target-price
Press the English button to read ...
https://www.nikkei.com/article/DGXZQOUC102E10Q1A810C2000000/
This article is for members only
Helios Approves Candidate for Treatment of Severe Pneumonia Within 21 Years
health care
October 5, 2021 11:00 [Paid members only]
Helios, a biotech company, will apply to the Ministry of Health, Labor and Welfare for manufacturing and marketing approval by the end of 2021 for a new drug candidate for the treatment of respiratory failure that occurs in patients with severe pneumonia. Good results were confirmed in the final stage clinical trial (clinical trial). Severe pneumonia is one of the causes of death in patients with the new coronavirus. If it can be put into practical use, treatment options will expand.
New drug candidates are for the treatment of acute respiratory distress syndrome (ARDS). ARDS causes respiratory failure when inflammatory cells attack the lungs and cause hypoxia. ...
This Article came out in Nikkei newspaper, which usually does not report until things are unofficially certain. Healios will file for approval in Japan this year and hopefully to start sales next year. I'm holding well OVER 6 figures worth of shares .. Hang in
https://www.nikkei.com/article/DGXZQOUC102E10Q1A810C2000000/
All of a sudden, the world is talking about stroke. Biogen buys a company to be in the game. Then there is talk about Roche being interested.
https://www.fiercebiotech.com/topic/acute-ischemic-stroke
The ??? is WHY did Gil step down WHY ??? Maybe he got an offer from Biogen and failed to mention it to the shareholders !!! Maybe Hardy found out about it and used it as leverage ??? If this kind of news doesn't get the ATHX exec's off their asses, nothing will. The Board should know that they can be sued--big time for not revealing allllllll of the above. Once Helios' trial succeeds, THIS ALL WILL COME TO A HEAD. Then, we will get ACTION and a BUYOUT INTEREST WILL DEFINETLY COME TO THE SURFACE .... I MEAN JAPANESE HEALTH AUTHORITY APPROVAL. Once they have that, they are in the market selling (Helios).
Now ATHX can sell additional licenses, can sell the company, can set up other partnerships. You don't need a CEO to sell a company. Maybe that's why they haven't hired a CEO yet .. JMO
THE BEST IS YET TO COME ... GOOD LUCK LONGS
Read use of proceeds regarding HEALIOS IR : Announcement of Issuance of New Shares through an International Offering .. GOOD LUCK LONGS
https://ssl4.eir-parts.net/doc/4593/tdnet/2025075/00.pdf
Just another heads up, short interest dropped 8% from 13,888,926 to 12,788,982. This decreasing trend has been consistent since 3-31-21 when short interest was at 26,040,188 ... GOOD LUCK LONGS
Healios CEO has just confirmed on Twitter that phase 3 topline stroke results will be out in Q4 2021 .. GOOD LUCK LONGS
We have completed the P2/3 acute stroke trials! (top line data in 4Q2021)
— Dr. Tadahisa "Hardy" Kagimoto, MD 鍵本 忠尚 (@HardyTSKagimoto) August 10, 2021
急性期脳梗塞の治験も患者組み込み並びに脱落が一定数以上無く解析に耐える事を確認しましたので、お知らせします(速報値4Q2021予定)https://t.co/AnPmHxkT5mhttps://t.co/h3QJb8q49d
Athersys, Inc. - Clinical Trials - Clinical Pipeline / WELL PRESENTED.
https://www.athersys.com/clinical-trials/clinical-pipeline/default.aspx
https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-001680-69/DE
https://www.reddit.com/r/ATHX/comments/ojwmjm/human_multipotent_adult_progenitor_cells/?%24deep_link=true&correlation_id=30a76e4a-951c-44f3-b84c-8d3bb214296e&post_fullname=t3_ojwmjm&post_index=1&ref=email_digest&ref_campaign=email_digest&ref_source=email&utm_content=post_title&%243p=e_as&_branch_match_id=829669447967134701
https://www.bizjournals.com/cleveland/news/2021/07/06/cleveland-center-to-train-for-cell-therapy-jobs.html
Dr. Alice Valentin-Torres of Athersys discusses the research and findings described in the recent Scientific Reports by Nature publication supporting the hypothesis of how MAPC® (MultiStem®) modulates immune responses under different clinical conditions ... GOOD LUCK LONGS
https://www.reddit.com/r/ATHX/comments/ocnujp/dr_alice_valentintorres_of_athersys_discusses_the/?utm_source=share&utm_medium=ios_app&utm_name=iossmf
Word is getting around SADLY toooooooo many are dying ...
https://news.yahoo.com/sepsis-prediction-tool-used-hospitals-131756802.html
Just my thinking with the recent Healios data will not be as compelling as the larger trial, but compelling enough for the Japanese government to approve it is still a scenario that I think the play will play out so the they can a steal shares before this breaks out .. I suppose that can be viewed in different ways though there are sideline sitters waiting for something GOOD to happen before participating ... let the big boys play while retail investors get fleeced short term and everything is probably up but to GILS HARD WORK here and we only know what we are told so Gil is probably sitting PRETTY and enjoying this rather just biding his time before the rocket takes off .. ATHX PPS will hit double digits after Japanese partner Healios releases releases Positive ARDS data along with full blown PMDA approval .. JMO ... GOOD LUCK LONGS
https://www.reddit.com/r/ATHX/comments/nqtyx2/proxy_voting/h0lwkd5/?%24deep_link=true
ATHX Latest update June Version ... GOOD LUCK LONGS
https://s23.q4cdn.com/674737627/files/doc_presentations/2021/06/06-03-2021-ATHX-Investor-Presentation-June.pdf
Billionaire Israel Englander LOVES T2
We’ll start in the healthcare industry, where T2 Biosystems is working to revolutionize diagnostics. The company offers diagnosticians and medical labs a range of devices based on its T2 Magnetic Resonance (T2MR) tech to quickly and accurately diagnosis a variety of septic illnesses. As the company notes, sepsis claims more lives annually than AIDS, breast cancer, and prostate cancer combined. Rapid and accurate diagnosis is the key for patient survival, and this is the niche that T2 aims to fill.
The company’s technology enables diagnostic blood tests with results available in a matter of hours, compared to the 1 to 5 days currently taken by most medical lab tests. Available testing products include the T2Bacteria Panel and the T2Candida panel, which are the only FDA-approved blood tests for septic agents that do not need to wait for a blood culture. A T2SARS-CoV-2 Panel is also available, using upper respiratory samples.
T2 has an active product pipeline, with rapid diagnostic tests on the drawing board for a variety of illnesses. Upcoming products include the T2Cauris panel and the T2Resistance panel. These testing products are currently designated for research use only (ROU) in the US. The T2Lyme panel, which will allow for faster diagnosis of the difficult-to-determine Lyme disease, is at an earlier stage of the development.
All of T2’s products operate on the same T2Dx instrument, allowing for interchangeability in the lab environment. The device offers a simple user interface, and operates with just 4ml of whole blood. T2 boasts that its device is in use in more than 200 hospitals worldwide.
In the first quarter of 2021, T2 saw top-line revenue grow by 173% year-over-year, to $7 million. This was driven by a 345% yoy increase in product revenue, to $4.7 million. Sepsis test utilization in the US rose by 85% yoy in the quarter, showing increasing acceptance of the device and technology.
Izzy Englander is among those that have high hopes for this healthcare name. In Q1, Englander's Millennium picked up over 1.36 million shares of TTOO stock, now valued at $1.5 million. This increased Englander’s stake in the company to 2.68 million shares, with a market value of $2.9 million.
5-star analyst Charles Duncan, of Canaccord, also counts himself as a fan. Duncan gives TTOO shares a Buy rating along with a $3.50 price target. This target conveys his confidence in TTOO's ability to soar 212% higher in the next twelve months. (To watch Duncan's track record, click here)
“T2’s +345% Y/Y product revenue growth is a positive datapoint for the company's post-pandemic commercial strategy, which is being supported by a scaling to just under 10 direct sales reps in Q1. We view the acquisitions of Cepheid, BioFire, GenMark, and Luminex as validation that the hospital lab is an attractive industry segment, given clinicians’ (and patients’) desire to shift away from centralized testing strategies to a more decentralized approach. With these four companies off the table, T2 should benefit from scarcity value. Separately, a more aggressive approach towards commercial execution should marry well with rising awareness around antimicrobial resistance and sepsis, in a post-pandemic environment that prioritizes infectious disease diagnostics," Duncan noted.
It turns out that other analysts also have high hopes. With 4 Buys and a single Hold, the word on the Street is that this stock, which currently going for $1.10 apiece, is a Strong Buy. In addition, the $2.83 average price target puts the upside potential at 156% ... GOOD LUCK LONGS
Lots of discussion regarding ARDs in Japan .. Hardy is going for overall ARDs approval and this must go to the overall strength of the results that they saw which he's highly confident of approval .. GOOD LUCK LONGS
Healios is building facilities before approval .. Good Luck Longs
https://ssl4.eir-parts.net/doc/4593/tdnet/1971157/00.pdf
https://www.reddit.com/r/ATHX/comments/nerr10/in_vivos_list_of_30_rising_leaders/?utm_source=share&utm_medium=ios_app&utm_name=iossmf
Hardy presented slides early this morning. Trial data is being analyzed and report will be coming soon. On slide #4 he had these note in bold:
Consulting with regulatory authorities !!
I am sure Hardy has seen all the data and knows the conclusion. So, by having the note printed in BOLD he's telegraphing an expectation of a quick approval ... GOOD LUCK LONGS
BOA presentation was kind of decent need to wait for the news.
No mention of shareholder authorization for increase in number of authorized shares .I think the proxy proposal is why would you NO vote for this ??? WHY they WILL only increase the outstanding shares, dilute your holdings, pay themselves undeserved bonuses, it's like giving the execs a chance to pick your pocket. Shareholders have never been rewarded in the past, just look at the current price, that tells you how the same old game will be played. They sell the stock through a shelf offering, the cash goes into the ATHX bank account, then into the exec's and employees bank account, as a shareholder GET NOTHING IN RETURN .. Ask yourself
WHY such a huge increase? Probably just to make it easy for the exec's etc to quickly turn the authorized into outstanding and they can SPEND shareholders monies AWAY without rewarding the shareholders YEAH RIGHT SPEND AWAY MY ####### ### If this company had a decent track record of rewarding shareholders, that might be different it's out of your pocket and into theirs. Don't get me wrong it's not only the exec getting rewarded the board went along with the BS .. Cannot give these people the vote is like voting a referendum for your politician to raise your taxes The $1.54 stock price is clear evidence. Hopefully there's positive news from Helios on the One Bridge results and in the long term it WILL BE THE SAMO samo it's just not RIGHT JMO .. GOOD LUCK LONGS
T2 Biosystems highlights the benefits of T2MR technology vs. blood culture .. GOOD LUCK LONGS
https://seekingalpha.com/news/3686059-t2-biosystems-highlights-the-benefits-of-t2mr-technology-vs-blood-culture
Yesterday's presentation by Ivor- CFO of ATHX.
Just amazing there was NO questions from audience.
ONLY the Moderator asks ?????????? Key take always --- With-in a month or two they should expect data from the ARDS Trials in Japans One Bridge. 2nd take away there were no ?????????? from the audience.
Commercialization of the product should take place in the next year, or two.
That was about it .. GOOD LUCK LONGS